Mindset Pharma Inc.

CSE: MSET

Company Logo

Company Overview

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. 

Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. The company is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds.

The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

Financial Highlights

$7,751,910

Revenue (ttm)

$3,905,607

Gross Profit (ttm)

-$0.06

Diluted EPS (ttm)

Management Team

Mr. James Andre-Charles Lanthier
Chief Exec. Officer

Mr. Arvin Ramos CPA
Chief Financial Officer

Mr. Joseph Araujo
Chief Scientific Officer, Member of Scientific Advisory Board & Director

Mr. Jason Atkinson
VP of Corp. Devel.

Dr. Abdelmalik Slassi Ph.D.
Sr. VP of Innovation & Member of Scientific Advisory Board

Chris Irwin
Corp. Sec.

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$18,655,094

Shares Outstanding
66,140,789

Shares Short (% of Float)
()

Insider Ownership
10%